Adoptive cell therapy for the treatment of patients with metastatic melanoma

Steven A. Rosenberg, Mark E. Dudley

Research output: Contribution to journalArticle

Abstract

Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response rates between 49% and 72% were seen. Persistence of infused cells in the circulation at one month was highly correlated with anti-tumor response as was the mean telomere length of the cells infused and the number of CD8+ CD27+ cells infused. Responses occur at all sites and appear to be durable with many patients in ongoing response beyond three years. In the most recent trial of 25 patients receiving maximum lymphodepletion, seven of the 25 patients (28%) achieved a complete response. Of the 12 patients in the three trials who achieved a complete response all but one are ongoing between 18 and 75 months. We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers.

Original languageEnglish (US)
Pages (from-to)233-240
Number of pages8
JournalCurrent Opinion in Immunology
Volume21
Issue number2
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Melanoma
Neoplasms
Therapeutics
Tumor-Infiltrating Lymphocytes
Telomere
T-Cell Antigen Receptor
Cell Count
Clinical Trials
Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Adoptive cell therapy for the treatment of patients with metastatic melanoma. / Rosenberg, Steven A.; Dudley, Mark E.

In: Current Opinion in Immunology, Vol. 21, No. 2, 04.2009, p. 233-240.

Research output: Contribution to journalArticle

Rosenberg, Steven A. ; Dudley, Mark E. / Adoptive cell therapy for the treatment of patients with metastatic melanoma. In: Current Opinion in Immunology. 2009 ; Vol. 21, No. 2. pp. 233-240.
@article{0d42355920594b039fc3260a6d188d04,
title = "Adoptive cell therapy for the treatment of patients with metastatic melanoma",
abstract = "Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response rates between 49{\%} and 72{\%} were seen. Persistence of infused cells in the circulation at one month was highly correlated with anti-tumor response as was the mean telomere length of the cells infused and the number of CD8+ CD27+ cells infused. Responses occur at all sites and appear to be durable with many patients in ongoing response beyond three years. In the most recent trial of 25 patients receiving maximum lymphodepletion, seven of the 25 patients (28{\%}) achieved a complete response. Of the 12 patients in the three trials who achieved a complete response all but one are ongoing between 18 and 75 months. We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers.",
author = "Rosenberg, {Steven A.} and Dudley, {Mark E.}",
year = "2009",
month = "4",
doi = "10.1016/j.coi.2009.03.002",
language = "English (US)",
volume = "21",
pages = "233--240",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Adoptive cell therapy for the treatment of patients with metastatic melanoma

AU - Rosenberg, Steven A.

AU - Dudley, Mark E.

PY - 2009/4

Y1 - 2009/4

N2 - Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response rates between 49% and 72% were seen. Persistence of infused cells in the circulation at one month was highly correlated with anti-tumor response as was the mean telomere length of the cells infused and the number of CD8+ CD27+ cells infused. Responses occur at all sites and appear to be durable with many patients in ongoing response beyond three years. In the most recent trial of 25 patients receiving maximum lymphodepletion, seven of the 25 patients (28%) achieved a complete response. Of the 12 patients in the three trials who achieved a complete response all but one are ongoing between 18 and 75 months. We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers.

AB - Adoptive cell therapy (ACT) is the best available treatment for patients with metastatic melanoma. In a recent series of three consecutive clinical trials using increasing lymphodepletion before infusion of autologous tumor infiltrating lymphocytes (TIL), objective response rates between 49% and 72% were seen. Persistence of infused cells in the circulation at one month was highly correlated with anti-tumor response as was the mean telomere length of the cells infused and the number of CD8+ CD27+ cells infused. Responses occur at all sites and appear to be durable with many patients in ongoing response beyond three years. In the most recent trial of 25 patients receiving maximum lymphodepletion, seven of the 25 patients (28%) achieved a complete response. Of the 12 patients in the three trials who achieved a complete response all but one are ongoing between 18 and 75 months. We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers.

UR - http://www.scopus.com/inward/record.url?scp=65249173447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249173447&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2009.03.002

DO - 10.1016/j.coi.2009.03.002

M3 - Article

C2 - 19304471

AN - SCOPUS:65249173447

VL - 21

SP - 233

EP - 240

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 2

ER -